Analysts Issue Forecasts for REGN FY2026 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Regeneron Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst C. Gould forecasts that the biopharmaceutical company will post earnings of $26.24 per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $695.00 price objective on the stock. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the prior year, the business posted $9.55 earnings per share.

A number of other analysts also recently issued reports on the stock. UBS Group cut their price target on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating for the company in a report on Thursday, June 5th. JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $700.00 to $580.00 in a research report on Friday, May 30th. Guggenheim reissued a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Finally, BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a report on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $836.48.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded up $3.30 during trading hours on Wednesday, hitting $521.90. 425,712 shares of the stock were exchanged, compared to its average volume of 871,312. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm's fifty day moving average price is $564.76 and its 200 day moving average price is $653.10. The company has a market cap of $56.35 billion, a P/E ratio of 13.63, a P/E/G ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.67%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of REGN. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $25,000. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares in the last quarter. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $28,000. E Fund Management Hong Kong Co. Ltd. boosted its position in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the period. Finally, Activest Wealth Management raised its position in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 21 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.